# PDUFA dates February 2026: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2026-02

> 280 FDA catalysts are dated in February 2026, including 10 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in February 2026?

PDUFA dates in February 2026: clemidsogene lanparvovec (RGNX) on February 8, 2026; REGENXBIO Inc. (RGNX) on February 8, 2026; MVASI® (bevacizumab, MRK) on February 20, 2026; BYSANTITM (milsaperidone, VNDA) on February 21, 2026; Bysanti (bysanti, VNDA) on February 21, 2026; DESMODA (desmopressin, ETON) on February 25, 2026; and 4 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2026-02)

Source: Press release filed with the SEC (EX-99), accession 0001193125-25-268101, https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/fda-calendar/2026-02#answer

## PDUFA dates in February 2026

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| February 8, 2026 | REGENXBIO Inc. | RGNX | clemidsogene lanparvovec |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-ex99_1.htm) |
| February 8, 2026 | REGENXBIO Inc. | RGNX |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-ex99_1.htm) |
| February 20, 2026 | Merck & Co., Inc. | MRK | MVASI® (bevacizumab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/tm2529620d1_ex99-1.htm) |
| February 21, 2026 | Vanda Pharmaceuticals Inc. | VNDA | BYSANTITM (milsaperidone) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007256/vnda8-k2112026exhibit991.htm) |
| February 21, 2026 | Vanda Pharmaceuticals Inc. | VNDA | Bysanti (bysanti) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda8-k10292025exhibit991.htm) |
| February 25, 2026 | Eton Pharmaceuticals, Inc. | ETON | DESMODA (desmopressin) |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774925022298/eton20250702_8k.htm) |
| February 25, 2026 | Eton Pharmaceuticals, Inc. | ETON | ET-600 |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/ex_854696.htm) |
| February 28, 2026 | BIOMARIN PHARMACEUTICAL INC | BMRN |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000002/earningsrelease-23feb26ex9.htm) |
| February 28, 2026 | REGENERON PHARMACEUTICALS, INC. | REGN | Dupixent (dupilumab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525285701/d895566dex991.htm) |
| February 28, 2026 | Ascendis Pharma A/S | ASND | TransCon (transcon) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312526046736/d73635dex991.htm) |

## All catalysts in February 2026

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 1, 2026 | [Joenja® (leniolisib) complete response letter (CRL)](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, complete response letter | "Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000004/pharminggroupreceivescompl.htm)) |
| February 1, 2026 | [REGN7544 primary completion](https://sec-api.dev/pdufa/regn7544) | REGN | Sepsis-Induced Hypotension | completed | "NCT06608901 (A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-01 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06608901)) |
| February 2, 2026 | [Anaphylm™ (dibutepinephrine) complete response letter (CRL)](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type I allergic reactions | completed, complete response letter | "On February 2, 2026, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026, for the New Drug Application (NDA) seeking approval of Anaphylm™ (dibutepinephrine) Sublingual Film for the treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more (approximately 66 pounds)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000005/aqst-20260130.htm)) |
| February 2, 2026 | [MIRA-55 trial start](https://sec-api.dev/pdufa/mira-55) | MIRA |  | completed | "February 2, 2026, MIRA Pharmaceuticals, Inc. (the "Company") announced that it has initiated dosing in the final cohort of its Phase 1 multiple ascending dose (MAD) clinical trial evaluating Ketamir-2, the Company's lead oral NMDA receptor antagonist." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1904286/000149315226004739/form8-k.htm)) |
| February 2, 2026 | [Twist Bioscience Corp earnings report](https://sec-api.dev/companies/twst/catalysts) | TWST |  | completed | "Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581280/000158128026000016/twst-20251231xex9913.htm)) |
| February 2, 2026 | [WELIREG® (belzutifan) primary completion](https://sec-api.dev/pdufa/belzutifan) | MRK | Carcinoma, Renal Cell | completed | "NCT04586231 (A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-02 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04586231)) |
| February 2, 2026 | [Inhaled treprostinil primary completion](https://sec-api.dev/pdufa/inhaled-treprostinil) | UTHR | Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease | completed | "NCT04708782 (Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-02 (ACTUAL); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04708782)) |
| February 2, 2026 | [Encorafenib primary completion](https://sec-api.dev/pdufa/encorafenib) | PFE | Melanoma | withdrawn | "NCT05926960 (A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-02-02 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05926960)) |
| February 3, 2026 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "NEW YORK, Tuesday, February 3, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000005/pfe-12312025xex99.htm)) |
| February 3, 2026 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "& Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_ex99-1.htm)) |
| February 3, 2026 | [NRC HEALTH earnings report](https://sec-api.dev/companies/nrc/catalysts) | NRC |  | completed | "NRC HEALTH ANNOUNCES FOURTH QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/70487/000143774926002726/ex_915251.htm)) |
| February 3, 2026 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815426000003/amgn-20251231earningsrelea.htm)) |
| February 3, 2026 | [Replimune Group, Inc. earnings report](https://sec-api.dev/companies/repl/catalysts) | REPL |  | completed | "Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926009510/tm264822d1_ex99-1.htm)) |
| February 3, 2026 | [Merck & Co., Inc. trial start](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "In 2025, the Company announced positive late-stage trial results from 18 Phase 3 trials and began enrolling patients in 21 new Phase 3 studies evaluating multiple indications and therapeutic areas, with approximately 80 Phase 3 studies currently underway." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_ex99-1.htm)) |
| February 3, 2026 | [KEYTRUDA® (pembrolizumab) FDA approval](https://sec-api.dev/pdufa/pembrolizumab) | PFE |  | completed, approved | "Pfizer and Astellas announced the U.S. Food and Drug Administration (FDA) approved Padcev in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as neoadjuvant treatment and then continued after cystectomy (surgery) as adjuvant treatment for adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000005/pfe-12312025xex99.htm)) |
| February 3, 2026 | [AYTU BIOPHARMA, INC earnings report](https://sec-api.dev/companies/aytu/catalysts) | AYTU |  | completed | "Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1385818/000143774926002799/ex_892737.htm)) |
| February 3, 2026 | [Brentuximab vedotin primary completion](https://sec-api.dev/pdufa/brentuximab-vedotin) | PFE | Melanoma; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck | completed | "NCT04609566 (Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-03 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04609566)) |
| February 3, 2026 | [Batoclimab primary completion](https://sec-api.dev/pdufa/batoclimab) | IMVT | Thyroid Eye Disease | completed | "NCT05524571 (Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-03 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05524571)) |
| February 3, 2026 | [NGI226 primary completion](https://sec-api.dev/pdufa/ngi226) | NVS | Achilles Tendinopathy | completed | "NCT05592990 (A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-03 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05592990)) |
| February 4, 2026 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000008/q425lillysalesandearningsp.htm)) |
| February 4, 2026 | [PHIBRO ANIMAL HEALTH CORP earnings report](https://sec-api.dev/companies/pahc/catalysts) | PAHC |  | completed | "Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069899/000110465926010345/pahc-20260204xex99d1.htm)) |
| February 4, 2026 | [BIO-TECHNE Corp earnings report](https://sec-api.dev/companies/tech/catalysts) | TECH |  | completed | "Minneapolis/February 4, 2026/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/842023/000110465926009994/tech-20260204xex99d1.htm)) |
| February 4, 2026 | [TEPKINLY (epcoritamab) FDA approval](https://sec-api.dev/pdufa/epcoritamab) | ABBV |  | completed, approved | "•AbbVie announced the FDA approval of Epkinly (epcoritamab) in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000004/abbv-20251231xexhibit991.htm)) |
| February 4, 2026 | [GRI Bio, Inc. earnings report](https://sec-api.dev/companies/gri/catalysts) | GRI |  | completed | "LA JOLLA, CA, February 4, 2026 -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases today summarized recently reported Full Year 2025 financial results, provided an update on the Company's current cash position and cash runway and summarized key clinical and corporate highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429326000040/ex991_pressreleaseye25earn.htm)) |
| February 4, 2026 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000004/abbv-20251231xexhibit991.htm)) |
| February 4, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Renal Cell | completed | "NCT04736706 (A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04736706)) |
| February 4, 2026 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Amyloidosis | completed | "NCT05250973 (A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05250973)) |
| February 4, 2026 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Open-Angle Glaucoma | completed | "NCT05411198 (Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05411198)) |
| February 4, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Renal Cell | completed | "NCT05899049 (A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05899049)) |
| February 4, 2026 | [AZD8630 primary completion](https://sec-api.dev/pdufa/azd8630) | AZN | Asthma | completed | "NCT06529419 (A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06529419)) |
| February 5, 2026 | [Biosimilar topline data readout](https://sec-api.dev/pdufa/biosimilar) | ALVO |  | completed, positive | "On 5 February 2026, the Group announced positive top-line results from its pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio (vedolizumab)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/alvo-20251231.htm)) |
| February 5, 2026 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000002/a2025q4ex991.htm)) |
| February 5, 2026 | [Adaptive Biotechnologies Corp earnings report](https://sec-api.dev/companies/adpt/catalysts) | ADPT |  | completed | "Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478320/000119312526039409/adpt-ex99_1.htm)) |
| February 5, 2026 | [Prestige Consumer Healthcare Inc. earnings report](https://sec-api.dev/companies/pbh/catalysts) | PBH |  | completed | "TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-February 5, 2026-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1295947/000129594726000006/exhibit991fy26-q3earningsr.htm)) |
| February 5, 2026 | [ARROWHEAD PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/arwr/catalysts) | ARWR |  | completed | "Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000087940726000033/arwr-202602058kex991.htm)) |
| February 5, 2026 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010633/tm265061d1_ex99-1.htm)) |
| February 5, 2026 | [IQVIA HOLDINGS INC. earnings report](https://sec-api.dev/companies/iqv/catalysts) | IQV |  | completed | "RESEARCH TRIANGLE PARK, N.C. - February 5, 2026 - IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478242/000162828026005605/iqv-q4x2025earningspressre.htm)) |
| February 5, 2026 | [Entyvio® (vedolizumab) topline data readout](https://sec-api.dev/pdufa/vedolizumab) | ALVO |  | completed, positive | "On 5 February 2026, the Group announced positive top-line results from its pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio (vedolizumab)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326003974/exh_993.htm)) |
| February 5, 2026 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo | completed | "NCT05583526 (A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-05 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05583526)) |
| February 5, 2026 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Skin Quality Deficit | completed | "NCT06547125 (A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-02-05 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06547125)) |
| February 6, 2026 | [LISRAYA™ (brepocitinib) earnings report](https://sec-api.dev/pdufa/brepocitinib) | ROIV |  | completed | "Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000009/q3fy2025roivantearningsrel.htm)) |
| February 6, 2026 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000010/exhibit991202626.htm)) |
| February 6, 2026 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen Inc. (Nasdaq: BIIB) today reported fourth quarter and full year 2025 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504526000011/exhibit991-q42025pressrele.htm)) |
| February 6, 2026 | [INO-3107 NDA/BLA submission](https://sec-api.dev/pdufa/ino-3107) | INO |  | completed | "For example, a purported shareholder class action complaint was filed against us on February 6, 2026 and three purported shareholder derivative complaints have been filed against us on March 5, 2026, March 16, 2026 and July 23, 2026, naming us and our executive officers as defendants, and alleging that we made materially false and misleading statements regarding the submission to the FDA and the FDA's review timeline for our BLA for INO-3107 in violation of certain federal securities laws." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1055726/000119312526326370/d155272d424b5.htm)) |
| February 6, 2026 | [Milvexian primary completion](https://sec-api.dev/pdufa/milvexian) | JNJ | Acute Coronary Syndrome | completed | "NCT05754957 (A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-06 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05754957)) |
| February 7, 2026 | [Clemidsogene lanparvovec complete response letter (CRL)](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | completed, complete response letter | "On February 7, 2026, the Company received a CRL from the FDA regarding the Company's BLA for RGX-121, the Company's investigational gene therapy for Mucopolysaccharidosis type II." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590877/000119312526043342/rgnx-20260207.htm)) |
| February 7, 2026 | [Clemidsogene complete response letter (CRL)](https://sec-api.dev/pdufa/clemidsogene) | RGNX |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 02/07/2026 for BL 125840 to REGENXBIO, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125840_20260207.pdf%22)) |
| February 8, 2026 | [Clemidsogene lanparvovec PDUFA date](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | completed, complete response letter | "Clemidsogene lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; PDUFA date February 8, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-ex99_1.htm)) |
| February 8, 2026 | [REGENXBIO Inc. PDUFA date](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | scheduled | "FDA PDUFA date is February 8, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-ex99_1.htm)) |
| February 9, 2026 | [Medpace Holdings, Inc. earnings report](https://sec-api.dev/companies/medp/catalysts) | MEDP |  | completed | "CINCINNATI, OHIO, February 9, 2026-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the fourth quarter and full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000004/medp-20260209exx991.htm)) |
| February 9, 2026 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "N.J., February 13, 2026- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2025, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390026015895/ea027694801ex99-1_citius.htm)) |
| February 9, 2026 | [Ameluz (ameluz) topline data readout](https://sec-api.dev/pdufa/ameluz) | BFRI |  | completed, met | "(February 9, 2026) — Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced positive and statistically significant top-line results from its Phase 3 clinical trial evaluating Ameluz® PDT with the red-light LED (RhodoLED®)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226005717/ex99-1.htm)) |
| February 9, 2026 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526042812/enta-ex99_1.htm)) |
| February 9, 2026 | [ANAVEX (anavex) earnings report](https://sec-api.dev/pdufa/anavex) | AVXL |  | completed | "Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its first quarter of fiscal 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1314052/000173112226000193/e7298_ex99-1.htm)) |
| February 9, 2026 | [CMND-100 topline data readout](https://sec-api.dev/pdufa/cmnd-100) | CMND |  | completed, positive | "Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1892500/000121390026013478/ea027611302ex99-1_clearmind.htm)) |
| February 9, 2026 | [Bivamelagon primary completion](https://sec-api.dev/pdufa/bivamelagon) | RYTM | Hypothalamic Obesity | completed | "NCT06046443 (A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-09 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.; Results First Posted 2026-10-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06046443)) |
| February 9, 2026 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | completed | "NCT06531538 (A Study to Learn About How a New Pneumococcal Vaccine Works in Children): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-09 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06531538)) |
| February 10, 2026 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-q42025xexx991.htm)) |
| February 10, 2026 | [IBio, Inc. earnings report](https://sec-api.dev/companies/ibio/catalysts) | IBIO |  | completed | "Exhibit 99.1 iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000003/ibio-20260210xex99d1.htm)) |
| February 10, 2026 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/exel2025q42025exhibit991.htm)) |
| February 10, 2026 | [EVO301 topline data readout](https://sec-api.dev/pdufa/evo301) | EVMN | moderate-to-severe AD in March 2025 | completed, positive | "On February 10, 2026, the Company announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-20260210.htm)) |
| February 10, 2026 | [Forazapadin trial start](https://sec-api.dev/pdufa/forazapadin) | MSLE | degenerative muscle diseases, today | completed | "First participant dosed Feb. 12, 2026, following regulatory clearance from the U.S. FDA and global regulators" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1421642/000117184326001965/exh_991.htm)) |
| February 10, 2026 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000003/exhibit991earningspressrel.htm)) |
| February 10, 2026 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20260210, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| February 10, 2026 | [Zanzalintinib NDA/BLA acceptance](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | previously treated metastatic CRC, when used in combination with atezolizumab | completed | "In February 2026, Exelixis announced that the FDA accepted its NDA for zanzalintinib as a treatment for patients with previously treated metastatic CRC, when used in combination with atezolizumab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/exel2025q42025exhibit991.htm)) |
| February 10, 2026 | [Translarna™ (ataluren) primary completion](https://sec-api.dev/pdufa/ataluren) | PTCT | Duchenne Muscular Dystrophy | withdrawn | "NCT01247207 (Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor PTC Therapeutics; Results First Posted 2026-10-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT01247207)) |
| February 10, 2026 | [SAR443122 primary completion](https://sec-api.dev/pdufa/sar443122) | SNY | Colitis Ulcerative | completed | "NCT05588843 (Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05588843)) |
| February 10, 2026 | [BIIB091 primary completion](https://sec-api.dev/pdufa/biib091) | BIIB | Relapsing Forms of Multiple Sclerosis | completed | "NCT05798520 (A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05798520)) |
| February 10, 2026 | [AZD5462 primary completion](https://sec-api.dev/pdufa/azd5462) | AZN | Chronic Heart Failure | completed | "NCT06299826 (A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06299826)) |
| February 10, 2026 | [NTLA-2002 primary completion](https://sec-api.dev/pdufa/ntla-2002) | NTLA | Hereditary Angioedema | completed | "NCT06634420 (HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor Intellia Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06634420)) |
| February 10, 2026 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-186 (Efficacy): submission_status AP, submission_status_date 20260210, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| February 11, 2026 | [Nuvectis Pharma, Inc. earnings report](https://sec-api.dev/companies/nvct/catalysts) | NVCT |  | completed | "Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013049/tm265090d1_ex99-1.htm)) |
| February 11, 2026 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "SAN DIEGO, Feb. 11, 2026 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447526000006/q4-2025xearningsrelease.htm)) |
| February 11, 2026 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312526045527/d218771dex991.htm)) |
| February 11, 2026 | [Verekitug topline data readout](https://sec-api.dev/pdufa/verekitug) | UPB | severe asthma now | completed, positive | "On February 11, 2026, the Company announced positive top-line data from the Phase 2 global, randomized, double-blind, placebo-controlled, dose-ranging, parallel group VALIANT clinical trial (NCT06196879) that evaluated the safety and efficacy of verekitug for up to 60 weeks, with a minimum of 24 weeks of treatment, in 478 adults with severe asthma." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/2022626/000119312526045500/d44802d8k.htm)) |
| February 11, 2026 | [INTEGRATED BIOPHARMA INC earnings report](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | completed | "HILLSIDE, NEW JERSEY (February 11, 2026) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1016504/000143774926003808/ex_917244.htm)) |
| February 11, 2026 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007256/vnda8-k2112026exhibit991.htm)) |
| February 11, 2026 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "NEW YORK, NY, February 11, 2026 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2025 and introduced full year 2026 guidance for Portfolio Receipts." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000002/rprx-20251231rpplcpressxre.htm)) |
| February 11, 2026 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/vktx-ex99_1.htm)) |
| February 12, 2026 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526048738/rare-ex99_1.htm)) |
| February 12, 2026 | [Karyopharm Therapeutics Inc. earnings report](https://sec-api.dev/companies/kpti/catalysts) | KPTI |  | completed | "Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1503802/000119312526047670/kpti-ex99_1.htm)) |
| February 12, 2026 | [Anebulo Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/aneb/catalysts) | ANEB |  | completed | "Texas (February 12, 2026) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended December 31, 2025, and recent updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815974/000149315226006428/ex99-1.htm)) |
| February 12, 2026 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000162828026007491/alny2025q4earningsrelease.htm)) |
| February 12, 2026 | [Adlai Nortye Group Ltd. trial start](https://sec-api.dev/companies/anl/catalysts) | ANL |  | completed | ""Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed in the United States in early February in its ongoing Phase 1 clinical trial of AN9025, a pan-RAS (ON) inhibitor." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1944552/000121390026015163/ea027676401ex99-1_adlai.htm)) |
| February 12, 2026 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000023/agio-21226xfyxex991earning.htm)) |
| February 12, 2026 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "CITY, Calif., February 12, 2026 - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926014287/tm265567d1_ex99-1.htm)) |
| February 12, 2026 | [CRISPR Therapeutics AG earnings report](https://sec-api.dev/companies/crsp/catalysts) | CRSP |  | completed | "CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1674416/000119312526048873/crsp-ex99_1.htm)) |
| February 12, 2026 | [TRUSELTIQ® (infigratinib) topline data readout](https://sec-api.dev/pdufa/infigratinib) | BBIO |  | completed, met | "On February 12, 2026, we reported positive Phase 3 Topline results from our PROPEL 3 study for oral infigratinib with the first statistically significant improvements in body proportionality in achondroplasia." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm)) |
| February 12, 2026 | [Ultragenyx Pharmaceutical Inc. NDA/BLA submission](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Earlier today the company received an Incomplete Response Letter (IRL) regarding its resubmitted BLA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526048738/rare-ex99_1.htm)) |
| February 12, 2026 | [Benitec Biopharma Inc. earnings report](https://sec-api.dev/companies/bntc/catalysts) | BNTC |  | completed | "HAYWARD, Calif., February 12, 2026 -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1808898/000119312526047742/bntc-ex99_1.htm)) |
| February 12, 2026 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/ex-991_q42025.htm)) |
| February 12, 2026 | [Organon & Co. earnings report](https://sec-api.dev/companies/ogn/catalysts) | OGN |  | completed | "Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821825/000110465926013888/tm266144d1_ex99-1.htm)) |
| February 12, 2026 | [Vistagen Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vtgn/catalysts) | VTGN |  | completed | "Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1411685/000162828026007715/vtgn-20260212xex991.htm)) |
| February 12, 2026 | [Zoetis Inc. earnings report](https://sec-api.dev/companies/zts/catalysts) | ZTS |  | completed | "PARSIPPANY, N.J. - February 12, 2026 - Zoetis Inc. (NYSE: ZTS), the world's leading animal health company, today reported its financial results for the fourth quarter and full year 2025 and provided full year guidance for 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1555280/000155528026000008/exhibit9912-31x25q4.htm)) |
| February 12, 2026 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces Third Quarter 2026 Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126004927/ef20064916_ex99-1.htm)) |
| February 12, 2026 | [Leqvio (inclisiran sodium) label expansion decision](https://sec-api.dev/pdufa/inclisiran) | NVS |  | completed, approved | "NDA214012 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260212, review_priority PRIORITY; sponsor_name NOVARTIS; product LEQVIO (INCLISIRAN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214012%22)) |
| February 12, 2026 | [VRDN-003 primary completion](https://sec-api.dev/pdufa/vrdn-003) | VRDN | Thyroid Eye Disease | completed | "NCT06625411 (An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-12 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06625411)) |
| February 12, 2026 | [BRINSUPRI® (brensocatib) primary completion](https://sec-api.dev/pdufa/brensocatib) | INSM | Hidradenitis Suppurativa | withdrawn | "NCT06685835 (A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-02-12 (ACTUAL); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06685835)) |
| February 12, 2026 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Dermatitis Atopic | completed | "NCT06790121 (A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-12 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06790121)) |
| February 13, 2026 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal first quarter ended December 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390026015894/ea027694701ex99-1_citius.htm)) |
| February 13, 2026 | [Edesa Biotech, Inc. earnings report](https://sec-api.dev/companies/edsa/catalysts) | EDSA |  | completed | "Edesa Biotech Reports Fiscal 1st Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1540159/000117184326000810/exh_991.htm)) |
| February 13, 2026 | [Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) FDA approval](https://sec-api.dev/pdufa/amivantamab-and-hyaluronidase-lpuj) | JNJ |  | completed, approved | "BLA761484 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260213, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761484%22)) |
| February 13, 2026 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/exhibit9912025q4pressrelea.htm)) |
| February 13, 2026 | [Bitopertin complete response letter (CRL)](https://sec-api.dev/pdufa/bitopertin) | IRON | erythropoietic protoporphyria | completed, complete response letter | "On February 13, 2026, Disc Medicine, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for the New Drug Application ("NDA") for bitopertin as a treatment for patients with erythropoietic protoporphyria ("EPP")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/iron-20260213.htm)) |
| February 13, 2026 | [INTEGRATED BIOPHARMA INC interim data readout](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | scheduled | "After taking into consideration our interim results and current projections, management believes that operations, together with the revolving credit facility will support our working capital requirements at least through the period ending February 13, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1016504/000143774925003744/inbp20241231_10q.htm)) |
| February 13, 2026 | [Troriluzole (bhv-4157) primary completion](https://sec-api.dev/pdufa/troriluzole-bhv-4157) | BHVN | Obsessive Compulsive Disorder | withdrawn | "NCT04708834 (Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-02-13 (ACTUAL); Lead Sponsor Biohaven Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04708834)) |
| February 13, 2026 | [Therasphere™ yttrium-90 glass microspheres primary completion](https://sec-api.dev/pdufa/theraspheretm-yttrium-90-glass-microspheres) | BSX | Inoperable Hepatocellular Carcinoma | completed | "NCT05016245 (MANDARIN (S6371)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-13 (ACTUAL); Lead Sponsor Boston Scientific Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05016245)) |
| February 13, 2026 | [Miricorilant (cohort a) primary completion](https://sec-api.dev/pdufa/miricorilant-cohort-a) | CORT |  | completed | "NCT06108219 (A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-13 (ACTUAL); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06108219)) |
| February 13, 2026 | [Tarcocimab primary completion](https://sec-api.dev/pdufa/tarcocimab) | KOD | Diabetic Retinopathy | completed | "NCT06270836 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-13 (ACTUAL); Lead Sponsor Kodiak Sciences Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06270836)) |
| February 13, 2026 | [Nda220707 complete response letter (CRL)](https://sec-api.dev/pdufa/nda220707) | IRON |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA220707_20260213.pdf%22)) |
| February 13, 2026 | [WAKIX® (pitolisant) label expansion decision](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | completed, approved | "NDA211150 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260213, review_priority PRIORITY; sponsor_name HARMONY; product WAKIX (PITOLISANT HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211150%22)) |
| February 16, 2026 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Urinary Bladder Neoplasms; Muscle-Invasive Bladder Cancer | completed | "NCT03661320 (A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-16 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03661320)) |
| February 16, 2026 | [Ratutrelvir (83-0060) non-randomised primary completion](https://sec-api.dev/pdufa/ratutrelvir-83-0060-non-randomised) | TRAW | COVID - 19 | completed | "NCT07157007 (Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-16 (ACTUAL); Lead Sponsor Traws Pharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07157007)) |
| February 17, 2026 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., February 17, 2026 -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-ex99_1.htm)) |
| February 17, 2026 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315226007190/ex99-1.htm)) |
| February 17, 2026 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/ef20066055_ex99-1.htm)) |
| February 17, 2026 | [MVASI® (bevacizumab) earnings report](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed | "(Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for the first quarter fiscal year 2026 and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926015887/tm266557d1_ex99-1.htm)) |
| February 17, 2026 | [Krystal Biotech, Inc. earnings report](https://sec-api.dev/companies/krys/catalysts) | KRYS |  | completed | "PITTSBURGH, February 17, 2026 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000018/a4q25exhibit991pr.htm)) |
| February 17, 2026 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "SAN DIEGO, February 17, 2026 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 31, 2025, and provided an update on its recent corporate activities." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000023/ex991q420258-k.htm)) |
| February 17, 2026 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526052741/idya-ex99_1.htm)) |
| February 17, 2026 | [Vay736 1ml pfs primary completion](https://sec-api.dev/pdufa/vay736) | NVS | Sjögrens Disease; Systemic Lupus Erythematosus; Rheumatoid Arthritis | completed | "NCT06293365 (Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06293365)) |
| February 18, 2026 | [Bausch Health Companies Inc. earnings report](https://sec-api.dev/companies/bhc/catalysts) | BHC |  | completed | "LAVAL, QC, February 18, 2026 - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth quarter and full-year 2025 financial results and other key updates for the quarter." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/885590/000088559026000020/ex991-q4x2025.htm)) |
| February 18, 2026 | [Sonelokimab earnings report](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | completed | "Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000121390026018967/ea027791001ex99-1_moonlake.htm)) |
| February 18, 2026 | [Zulresso (brexanolone) trial start](https://sec-api.dev/pdufa/brexanolone) | LPCN |  | completed | "Based on observed comparable exposure of LPCN 1154 and IV brexanolone in the dosing confirmation study, we have confirmed the target dosing regimen and initiated a Phase 3 safety and efficacy study and, as of February 18, 2026, we had completed enrollment, dosing and the last patient's last visit in the Phase 3 pivotal trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/form10-k.htm)) |
| February 18, 2026 | [Stenoparib trial start](https://sec-api.dev/pdufa/stenoparib) | ALLR | relapsed small cell lung cancer | completed | "On February 18, 2026, the company announced that the first patients have been dosed in a VA funded investigator-initiated Phase 2 trial evaluating Stenoparib for the treatment of relapsed small cell lung cancer." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/allr20251231_10k.htm)) |
| February 18, 2026 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056020/nams-ex99_1.htm)) |
| February 18, 2026 | [CHARLES RIVER LABORATORIES INTERNATIONAL, INC. earnings report](https://sec-api.dev/companies/crl/catalysts) | CRL |  | completed | "WILMINGTON, MA, February 18, 2026 - Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth quarter and full-year 2025 and provided guidance for 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1100682/000110068226000020/crl4q25earningsrelease.htm)) |
| February 18, 2026 | [Talazoparib plus enzalutamide primary completion](https://sec-api.dev/pdufa/talazoparib-plus-enzalutamide) | PFE | Prostate Cancer | completed | "NCT04821622 (Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-18 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04821622)) |
| February 19, 2026 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm)) |
| February 19, 2026 | [Aglatimagene FDA approval](https://sec-api.dev/pdufa/aglatimagene) | CADL |  | completed, approved | "On February 19, 2026, Candel announced a $100 million royalty funding agreement with funds managed by RTW Investments, LP (RTW), subject to FDA approval of aglatimagene in localized, intermediate- to high-risk, prostate cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526222892/cadl-ex99_1.htm)) |
| February 19, 2026 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000012/ardx-20251231xexhibit991.htm)) |
| February 19, 2026 | [PROTHENA CORP PUBLIC LTD CO earnings report](https://sec-api.dev/companies/prta/catalysts) | PRTA |  | completed | "Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1559053/000155905326000003/exhibit991q42025earningsre.htm)) |
| February 19, 2026 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000022/spyre-20251231xexx991.htm)) |
| February 19, 2026 | [Vir Biotechnology, Inc. earnings report](https://sec-api.dev/companies/vir/catalysts) | VIR |  | completed | "Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1706431/000162828026010740/a20260223-q4ex992earningsr.htm)) |
| February 19, 2026 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/tmb-20260219xex99d1.htm)) |
| February 19, 2026 | [Miudella (miudella) FDA approval](https://sec-api.dev/pdufa/miudella) | OGN |  | completed, approved | "On February 19, 2026, we entered into an exclusive license agreement with Sebela for the global rights to Miudella®, a hormone-free copper intrauterine device ("IUD") that was approved by the FDA on February 24, 2025 and is estimated to launch commercials sales in the United States in late 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821825/000162828026051230/ogn-20260630.htm)) |
| February 19, 2026 | [Calquence (acalabrutinib) label expansion decision](https://sec-api.dev/pdufa/acalabrutinib) | AZN |  | completed, approved | "NDA210259 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260219, review_priority STANDARD; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210259%22)) |
| February 19, 2026 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828026009476/exhibit991.htm)) |
| February 19, 2026 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/aex991_2025q4x10xkearnings.htm)) |
| February 19, 2026 | [Alpha 1-antitrypsin primary completion](https://sec-api.dev/pdufa/alpha-1-antitrypsin) | KMDA | Alpha 1-Antitrypsin Deficiency | withdrawn | "NCT04204252 (Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-02-19 (ACTUAL); Lead Sponsor Kamada, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04204252)) |
| February 19, 2026 | [Lorigerlimab primary completion](https://sec-api.dev/pdufa/lorigerlimab) | MGNX |  | completed | "NCT05848011 (A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-19 (ACTUAL); Lead Sponsor MacroGenics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05848011)) |
| February 19, 2026 | [Venclexta (venetoclax) label expansion decision](https://sec-api.dev/pdufa/venetoclax) | ABBV |  | completed, approved | "NDA208573 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20260219, review_priority STANDARD; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22)) |
| February 20, 2026 | [MVASI® (bevacizumab) PDUFA date](https://sec-api.dev/pdufa/bevacizumab) | MRK |  | scheduled | "FDA Set PDUFA Date of Feb. 20, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/tm2529620d1_ex99-1.htm)) |
| February 20, 2026 | [BYSANTITM (milsaperidone) FDA approval](https://sec-api.dev/pdufa/milsaperidone) | VNDA | schizophrenia in adults | completed, approved | "On February 20, 2026, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release announcing that the U.S. Food and Drug Administration has approved BysantiTM (milsaperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and the treatment of schizophrenia in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026010376/vnda-20260220.htm)) |
| February 20, 2026 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036126006781/ef20066393_ex99-1.htm)) |
| February 20, 2026 | [LN-145 primary completion](https://sec-api.dev/pdufa/ln-145) | IOVA |  | withdrawn | "NCT03645928 (Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-02-20 (ACTUAL); Lead Sponsor Iovance Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03645928)) |
| February 20, 2026 | [XPOVIO® (selinexor) primary completion](https://sec-api.dev/pdufa/selinexor) | KPTIQ | Myelofibrosis | completed | "NCT04562389 (Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-20 (ACTUAL); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04562389)) |
| February 20, 2026 | [Volixibat primary completion](https://sec-api.dev/pdufa/volixibat) | MIRM | Primary Sclerosing Cholangitis | completed | "NCT04663308 (A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-20 (ACTUAL); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04663308)) |
| February 20, 2026 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Warm Autoimmune Hemolytic Anemia (wAIHA) | completed | "NCT05648968 (A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-20 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05648968)) |
| February 21, 2026 | [BYSANTITM (milsaperidone) PDUFA date](https://sec-api.dev/pdufa/milsaperidone) | VNDA |  | completed, approved | "•BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007256/vnda8-k2112026exhibit991.htm)) |
| February 21, 2026 | [Imsidolimab NDA/BLA submission](https://sec-api.dev/pdufa/imsidolimab) | VNDA |  | scheduled | ""We are particularly encouraged by our advancing pipeline, with multiple near-term regulatory milestones: the tradipitant NDA for motion sickness under FDA review with a PDUFA target action date of December 30, 2025; the Bysanti NDA for bipolar I disorder and schizophrenia also under FDA review with a PDUFA target action date of February 21, 2026; and the anticipated Q4 submission of the imsidolimab BLA for generalized pustular psoriasis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda8-k10292025exhibit991.htm)) |
| February 21, 2026 | [Bysanti (bysanti) PDUFA date](https://sec-api.dev/pdufa/bysanti) | VNDA |  | scheduled | "•Bysanti™ NDA for bipolar I disorder and schizophrenia is under review by the FDA with a PDUFA target action date of February 21, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda8-k10292025exhibit991.htm)) |
| February 21, 2026 | [Bysanti (bysanti) NDA/BLA acceptance](https://sec-api.dev/pdufa/bysanti) | VNDA |  | scheduled | "•Bysanti™ NDA for bipolar I disorder and schizophrenia accepted for filing by the FDA with a PDUFA target action date of February 21, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda8-k572025exhibit991.htm)) |
| February 23, 2026 | [Pariglasgene brecaparvovec NDA/BLA acceptance](https://sec-api.dev/pdufa/pariglasgene-brecaparvovec) | RARE | Glycogen Storage Disease Type Ia | completed | "On February 23, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted for review the Biologics License Application (the "BLA") seeking approval of DTX401 AAV gene therapy (pariglasgene brecaparvovec) for the treatment of Glycogen Storage Disease Type Ia (GSDIa)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526062568/rare-20260223.htm)) |
| February 23, 2026 | [Summit Therapeutics Inc. earnings report](https://sec-api.dev/companies/smmt/catalysts) | SMMT |  | completed | "1 Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000014/a2026_prx0223xq4ye2025ea.htm)) |
| February 23, 2026 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm)) |
| February 23, 2026 | [MR-141 NDA/BLA acceptance](https://sec-api.dev/pdufa/mr-141) | VTRS | presbyopia | completed | "•In February 2026, the Company announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm)) |
| February 23, 2026 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "SAN RAFAEL, Calif., February 23, 2026 - BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000002/earningsrelease-23feb26ex9.htm)) |
| February 23, 2026 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000017/exhibit991tarsus2232026pre.htm)) |
| February 23, 2026 | [Oric Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/oric/catalysts) | ORIC |  | completed | "ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526063974/oric-ex99_1.htm)) |
| February 23, 2026 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm)) |
| February 23, 2026 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-75 (Efficacy): submission_status AP, submission_status_date 20260223, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| February 23, 2026 | [Empliciti (elotuzumab) primary completion](https://sec-api.dev/pdufa/elotuzumab) | BMY | Multiple Myeloma | completed | "NCT02719613 (Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02719613)) |
| February 23, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | completed | "NCT05301842 (Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05301842)) |
| February 23, 2026 | [JNJ-81201887 primary completion](https://sec-api.dev/pdufa/jnj-81201887) | JNJ | Geographic Atrophy | completed | "NCT05811351 (A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05811351)) |
| February 23, 2026 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed | "NCT05831176 (A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05831176)) |
| February 23, 2026 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Asthma | completed | "NCT06102005 (Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06102005)) |
| February 23, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | NVCR | Non-Small Cell Lung Cancer (NSCLC) | withdrawn | "NCT06558799 (LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor NovoCure GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06558799)) |
| February 23, 2026 | [Avtx-009 regimen 1 primary completion](https://sec-api.dev/pdufa/avtx-009-regimen-1) | AVTX | Hidradenitis Suppurativa | completed | "NCT06603077 (A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Avalo Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06603077)) |
| February 24, 2026 | [Elanco Animal Health Inc earnings report](https://sec-api.dev/companies/elan/catalysts) | ELAN |  | completed | "Indianapolis, IN (February 24, 2026) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2025 and provided initial guidance for both the first quarter and full year 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739104/000173910426000008/elanco-12312025exhibit991.htm)) |
| February 24, 2026 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported fourth quarter and full year 2025 financial results, business achievements and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465926018837/tm266992d1_ex99-1.htm)) |
| February 24, 2026 | [AbCellera Biologics Inc. earnings report](https://sec-api.dev/companies/abcl/catalysts) | ABCL |  | completed | "VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000010/a2025earningspressrelease.htm)) |
| February 24, 2026 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000119312526065190/fulc-ex99_1.htm)) |
| February 24, 2026 | [Rapamycin topline data readout](https://sec-api.dev/pdufa/rapamycin) | PVLA |  | completed, positive | "WAYNE, Pa., February 24, 2026 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat participants suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced positive topline results from the Company's Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526065159/pvla-ex99_1.htm)) |
| February 24, 2026 | [STANDARD BIOTOOLS INC. earnings report](https://sec-api.dev/companies/lab/catalysts) | LAB |  | completed | "Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1162194/000119312526067026/lab-ex99_1.htm)) |
| February 24, 2026 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "HARMONY BIOSCIENCES REPORTS STRONG 2025 FINANCIAL RESULTS AND REITERATES 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224xex99d1.htm)) |
| February 24, 2026 | [REPLIGEN CORP earnings report](https://sec-api.dev/companies/rgen/catalysts) | RGEN |  | completed | "Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/730272/000119312526065246/rgen-ex99_1.htm)) |
| February 24, 2026 | [Vaxcyte, Inc. earnings report](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | completed | "Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/pcvx-20260224xexx991.htm)) |
| February 24, 2026 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026010865/q42025earningsrelease.htm)) |
| February 24, 2026 | [Beam Therapeutics Inc. earnings report](https://sec-api.dev/companies/beam/catalysts) | BEAM |  | completed | "Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745999/000119312526065191/beam-ex99_1.htm)) |
| February 24, 2026 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000012/a4q25financialpr.htm)) |
| February 24, 2026 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526067012/cytk-ex99_1.htm)) |
| February 24, 2026 | [ACI-19764 trial start](https://sec-api.dev/pdufa/aci-19764) | ACIU |  | completed | "ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that the first participant has been dosed in a Phase 1 clinical trial of ACI-19764, an orally administered small molecule inhibitor of the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651625/000095010326002519/dp241987_ex9901.htm)) |
| February 24, 2026 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000014/knsa-20260224xex99d1.htm)) |
| February 24, 2026 | [Attruby (acoramidis) earnings report](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed | "PALO ALTO, Calif., February 24, 2026 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on Attruby's commercial progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20251231xex9911.htm)) |
| February 24, 2026 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm)) |
| February 24, 2026 | [Cosentyx (secukinumab) primary completion](https://sec-api.dev/pdufa/secukinumab) | NVS | Giant Cell Arteritis | completed | "NCT05380453 (Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-24 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05380453)) |
| February 24, 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | NonSegmental Vitiligo | completed | "NCT06113445 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-24 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06113445)) |
| February 24, 2026 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Bipolar Disorder, Manic | completed | "NCT06462586 (Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-24 (ACTUAL); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06462586)) |
| February 25, 2026 | [AMARIN CORP PLCUK earnings report](https://sec-api.dev/companies/amrn/catalysts) | AMRN |  | completed | "Amarin Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/897448/000119312526068511/amrn-ex99_1.htm)) |
| February 25, 2026 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000038/exhibit991-10xk25.htm)) |
| February 25, 2026 | [ET-600 NDA/BLA acceptance](https://sec-api.dev/pdufa/et-600) | ETON |  | scheduled | ""In addition to our strong commercial performance, we continued to advance our pipeline programs and received favorable news when our New Drug Application (NDA) for ET-600 was accepted for review by the FDA and assigned a Prescription Drug User Fee Act (PDUFA) date of February 25, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/ex_854696.htm)) |
| February 25, 2026 | [MARAVAI LIFESCIENCES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/mrvi/catalysts) | MRVI |  | completed | "MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1823239/000182323926000005/exhibit991-q42025.htm)) |
| February 25, 2026 | [Alector, Inc. earnings report](https://sec-api.dev/companies/alec/catalysts) | ALEC |  | completed | "Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1653087/000119312526071557/alec-ex99_1.htm)) |
| February 25, 2026 | [DESMODA (desmopressin) PDUFA date](https://sec-api.dev/pdufa/desmopressin) | ETON |  | completed, approved | "On July 8, 2025, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company's New Drug Application for ET-600, a proprietary patented formulation of desmopressin oral solution, was accepted for review by the Food and Drug Administration (FDA) and assigned a Prescription Drug User Fee Administration target action date of February 25, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774925022298/eton20250702_8k.htm)) |
| February 25, 2026 | [IONIS PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/ions/catalysts) | IONS |  | completed | "Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036126006718/ef20066495_ex99-1.htm)) |
| February 25, 2026 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312526071566/srpt-ex99_1.htm)) |
| February 25, 2026 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000119312526071974/d23292dex991.htm)) |
| February 25, 2026 | [Revolution Medicines, Inc. earnings report](https://sec-api.dev/companies/rvmd/catalysts) | RVMD |  | completed | "Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1628171/000119312526071517/rvmd-ex99_1.htm)) |
| February 25, 2026 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312526068512/alks-ex99_1.htm)) |
| February 25, 2026 | [Arcus Biosciences, Inc. earnings report](https://sec-api.dev/companies/rcus/catalysts) | RCUS |  | completed | "Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000007/a2025q48kexhibit991.htm)) |
| February 25, 2026 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526071674/acad-ex99_1.htm)) |
| February 25, 2026 | [IMMUTEP Ltd trial start](https://sec-api.dev/companies/immp/catalysts) | IMMP |  | completed | "In September, Immutep announced the launch of an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in early-stage HR+/HER2-negative breast cancer patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506184/000119312526072723/d31342dex991.htm)) |
| February 25, 2026 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000010/mirm-20260225xexx991.htm)) |
| February 25, 2026 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926019658/tm267184d1_ex99-1.htm)) |
| February 25, 2026 | [ET-600 PDUFA date](https://sec-api.dev/pdufa/et-600) | ETON |  | scheduled | "ET-600 NDA accepted for review, assigned PDUFA date of February 25, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/ex_854696.htm)) |
| February 25, 2026 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000007/exhibit991uthr12312025.htm)) |
| February 25, 2026 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000119312526068523/d67820dex991.htm)) |
| February 25, 2026 | [Xencor Inc earnings report](https://sec-api.dev/companies/xncr/catalysts) | XNCR |  | completed | "Xencor Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000014/xncr-20260225xexx991.htm)) |
| February 25, 2026 | [DESMODA (desmopressin) FDA approval](https://sec-api.dev/pdufa/desmopressin) | ETON |  | completed, approved | "DEER PARK, Ill., FEB 25, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Food and Drug Administration (FDA) approval of a New Drug Application (NDA) for DESMODA™ (desmopressin acetate) Oral Solution for the management of central diabetes insipidus, also known as arginine vasopressin deficiency (AVP-D), as antidiuretic replacement therapy for patients of all ages." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774926005537/ex_923604.htm)) |
| February 25, 2026 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000009/sdgr-20251231xexx991.htm)) |
| February 25, 2026 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports fourth quarter and full year 2025 financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/ef20066378_ex99-1.htm)) |
| February 25, 2026 | [RMC-5127 trial start](https://sec-api.dev/pdufa/rmc-5127) | RVMD |  | completed | "The company recently advanced its fourth RAS(ON) inhibitor, the RAS(ON) G12V-selective inhibitor RMC-5127, into the clinic and announced that the first patient was dosed in a first-in-human trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1628171/000119312526071517/rvmd-ex99_1.htm)) |
| February 25, 2026 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000017/pressreleaseex991q42025.htm)) |
| February 25, 2026 | [Tin816 70 mg lyophilisate powder primary completion](https://sec-api.dev/pdufa/tin816) | NVS | Acute Kidney Injury Due to Sepsis | completed | "NCT05996835 (Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-25 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05996835)) |
| February 26, 2026 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076522/sndx-ex99_1.htm)) |
| February 26, 2026 | [Wave Life Sciences, Inc. earnings report](https://sec-api.dev/companies/wve/catalysts) | WVE |  | completed | "Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1631574/000119312526073437/d103046dex991.htm)) |
| February 26, 2026 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926020070/acrs-20260226xex99d1.htm)) |
| February 26, 2026 | [Xenon Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/xene/catalysts) | XENE |  | completed | "Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526076530/xene-ex99_1.htm)) |
| February 26, 2026 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312526073421/vera-ex99_1.htm)) |
| February 26, 2026 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000020/ex991pressreleaseq42025.htm)) |
| February 26, 2026 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm)) |
| February 26, 2026 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828026012003/ex991earningsreleaseq42025.htm)) |
| February 26, 2026 | [PERRIGO Co plc earnings report](https://sec-api.dev/companies/prgo/catalysts) | PRGO |  | completed | "Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000006/cy25q4ex991pressrelease-sh.htm)) |
| February 26, 2026 | [Pulmatrix, Inc. earnings report](https://sec-api.dev/companies/pulm/catalysts) | PULM |  | completed | "Announces Year-End and Fourth Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1574235/000149315226008129/ex99-1.htm)) |
| February 26, 2026 | [Relay Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rlay/catalysts) | RLAY |  | completed | "Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1812364/000119312526076617/rlay-ex99_1.htm)) |
| February 26, 2026 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000007/amph-20260226xex99d1.htm)) |
| February 26, 2026 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526073509/mnkd-ex99_1.htm)) |
| February 26, 2026 | [BRUKINSA® (zanubrutinib) earnings report](https://sec-api.dev/pdufa/zanubrutinib) | ONC |  | completed | "BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/exhibit991-q42025earningsr.htm)) |
| February 26, 2026 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020494/tm267321d1_ex99-1.htm)) |
| February 26, 2026 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073377/d119012dex991.htm)) |
| February 26, 2026 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012238/pcrx-12312025x991.htm)) |
| February 26, 2026 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/ef20066645_ex99-1.htm)) |
| February 26, 2026 | [Navenibart interim data readout](https://sec-api.dev/pdufa/navenibart) | BCRX |  | completed, positive | "On February 26, 2026, we announced that new positive, interim results from the long-term, open-label ALPHA-SOLAR trial show sustained, robust HAE attack suppression with navenibart administered every three and six months." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828026031238/bcrx-20260331.htm)) |
| February 26, 2026 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312526073363/d713689dex991.htm)) |
| February 26, 2026 | [Vyvgart (efgartigimod alfa) topline data readout](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX | ocular myasthenia gravis | completed, positive | "SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART® (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis (oMG)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926020017/tm267379d1_ex99-1.htm)) |
| February 26, 2026 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000119312526076595/orgo-ex99_1.htm)) |
| February 26, 2026 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000119312526076627/janx-ex99_1.htm)) |
| February 26, 2026 | [CRESCENT BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | completed | "Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828026011988/pressrelease-q42025.htm)) |
| February 26, 2026 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000012/ebs2025-12x31exhibit99er.htm)) |
| February 26, 2026 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm4q2025earningspr_v1.htm)) |
| February 26, 2026 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926005869/ex_916496.htm)) |
| February 26, 2026 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/d105707dex991.htm)) |
| February 26, 2026 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526073594/iron-ex99_1.htm)) |
| February 26, 2026 | [ATI-052 trial start](https://sec-api.dev/pdufa/ati-052) | ACRS |  | completed | "Announced Initiation of Two Phase 1b Proof-of-Concept (POC) Trials of ATI-052: Following positive interim Phase 1a SAD/MAD results, the Company has initiated Phase 1b POC studies in AD and asthma." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926020070/acrs-20260226xex99d1.htm)) |
| February 26, 2026 | [IMMUNIC, INC. earnings report](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed | "IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the year ended December 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000181/e665186_ex99-1.htm)) |
| February 26, 2026 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000011/nvaxq4-25earningspressrele.htm)) |
| February 26, 2026 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926020108/tm266859d1_ex99-1.htm)) |
| February 26, 2026 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000019/drafpr12312025.htm)) |
| February 26, 2026 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526073386/kymr-ex99_1.htm)) |
| February 26, 2026 | [OPKO HEALTH, INC. earnings report](https://sec-api.dev/companies/opk/catalysts) | OPK |  | completed | "OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/944809/000119312526076575/opk-ex99_1.htm)) |
| February 26, 2026 | [Entrada Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trda/catalysts) | TRDA |  | completed | "Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000009/entradatherapeuticsreports.htm)) |
| February 26, 2026 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073689/fate-ex99_1.htm)) |
| February 26, 2026 | [Tectonic Therapeutic, Inc. earnings report](https://sec-api.dev/companies/tecx/catalysts) | TECX |  | completed | "Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1681087/000119312526076843/tecx-ex99_1.htm)) |
| February 26, 2026 | [C4 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cccc/catalysts) | CCCC |  | completed | "C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662579/000162828026011971/cccc-20260226xexx991.htm)) |
| February 26, 2026 | [BRIUMVI® (ublituximab) earnings report](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed | "TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774926005733/ex_887198.htm)) |
| February 26, 2026 | [Ginkgo Bioworks Holdings, Inc. earnings report](https://sec-api.dev/companies/dna/catalysts) | DNA |  | completed | "Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830214/000162828026012339/ex991earningspr.htm)) |
| February 26, 2026 | [COLLEGIUM PHARMACEUTICAL, INC earnings report](https://sec-api.dev/companies/coll/catalysts) | COLL |  | completed | "Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1267565/000162828026011990/coll-2025x12x31xex99x1.htm)) |
| February 26, 2026 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000119312526073502/hrtx-ex99_1.htm)) |
| February 26, 2026 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184326001119/exh_991.htm)) |
| February 26, 2026 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062026000015/exhibit991_q42025earningsr.htm)) |
| February 26, 2026 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "SHANGHAI & CAMBRIDGE, Mass., February 26, 2026 -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2025, along with recent product highlights and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm)) |
| February 26, 2026 | [Elrexfio (elranatamab) primary completion](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | completed | "NCT05020236 (A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-02-26 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05020236)) |
| February 26, 2026 | [Tozorakimab 1 primary completion](https://sec-api.dev/pdufa/tozorakimab-1) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT05742802 (Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-26 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05742802)) |
| February 26, 2026 | [We complete response letter (CRL)](https://sec-api.dev/pdufa/we) | AMPH |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761403_20260226.pdf%22)) |
| February 27, 2026 | [TARA-002 interim data readout](https://sec-api.dev/pdufa/tara-002) | TARA | carcinoma in situ or CIS | scheduled | "On February 27, 2026, the Company will present updated interim data from its ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1)" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1359931/000121390026019617/ea0277972-8k_protara.htm)) |
| February 27, 2026 | [ZYNYZ (retifanlimab) complete response letter (CRL)](https://sec-api.dev/pdufa/retifanlimab) | INCY |  | completed, complete response letter | "On February 27, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for the supplemental Biologics License Application ("sBLA") for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer ("NSCLC") in combination with platinum-based chemotherapy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/879169/000087916926000013/incy-20260227.htm)) |
| February 27, 2026 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000008/amrx-q42025ex991.htm)) |
| February 27, 2026 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000013/anip-20260227xexx991.htm)) |
| February 27, 2026 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "BRANFORD, Conn. - February 27, 2026 — Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000014/aztrpressrelease12312025-e.htm)) |
| February 27, 2026 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079452/ck0001991792-ex99_1.htm)) |
| February 27, 2026 | [ALX ONCOLOGY HOLDINGS INC earnings report](https://sec-api.dev/companies/alxo/catalysts) | ALXO |  | completed | "ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810182/000119312526079342/alxo-ex99_1.htm)) |
| February 27, 2026 | [Prezcobix (cobicistat; darunavir and cobicistat; darunavir ethanolate) FDA approval](https://sec-api.dev/pdufa/cobicistat-darunavir-and-cobicistat-darunavir-ethanolate) | JNJ |  | completed, approved | "NDA220092 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20260227, review_priority STANDARD; sponsor_name JANSSEN PRODS; product PREZCOBIX (COBICISTAT; DARUNAVIR AND COBICISTAT; DARUNAVIR ETHANOLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220092%22)) |
| February 27, 2026 | [Prezcobix (cobicistat; darunavir ethanolate) label expansion decision](https://sec-api.dev/pdufa/cobicistat-darunavir-ethanolate) | JNJ |  | completed, approved | "NDA205395 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20260227, review_priority STANDARD; sponsor_name JANSSEN PRODS; product PREZCOBIX (COBICISTAT; DARUNAVIR ETHANOLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205395%22)) |
| February 27, 2026 | [YUVIWEL® (navepegritide) FDA approval](https://sec-api.dev/pdufa/navepegritide) | ASND |  | completed, approved | "Yuviwel \| navepegritide \| 2/27/2026 \| To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| February 27, 2026 | [Cetylpyridinium chloride (cpc), zinc lactate and sodium fluoride mouthwash primary completion](https://sec-api.dev/pdufa/cetylpyridinium-cpc-zinc-lactate-and-fluoride-mouthwash) | CL | Gingivitis; Plaque, Dental | completed | "NCT07263698 (Investigation of Clinical Efficacy of a New Mouthwash on Reducing Dental Plaque and Helping Prevent Gum Problems as Compared to a Control Mouthwash): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-27 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07263698)) |
| February 27, 2026 | [Sogroya (somapacitan-beco) label expansion decision](https://sec-api.dev/pdufa/somapacitan-beco) | NVO |  | completed, approved | "BLA761156 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20260227, review_priority STANDARD; sponsor_name NOVO NORDISK INC; product SOGROYA (SOMAPACITAN-BECO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761156%22)) |
| February 28, 2026 | [BIOMARIN PHARMACEUTICAL INC PDUFA date](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | scheduled | "•U.S. PDUFA date for the adolescent label expansion February 28, 2026; EU approval 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000002/earningsrelease-23feb26ex9.htm)) |
| February 28, 2026 | [Dupixent (dupilumab) PDUFA date](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "Dupixent sBLA accepted for priority review by the US FDA with a target action date of February 28, 2026; if approved, Dupixent would be the first and only medicine indicated specifically for AFRS, which would be its ninth FDA-approved indication" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525285701/d895566dex991.htm)) |
| February 28, 2026 | [TransCon (transcon) PDUFA date](https://sec-api.dev/pdufa/transcon) | ASND |  | scheduled | "- TransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312526046736/d73635dex991.htm)) |

Other months: https://sec-api.dev/fda-calendar/2026-01 , https://sec-api.dev/fda-calendar/2026-03. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates February 2026: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2026-02

```bibtex
@misc{secapidev_fda_calendar_2026_02_20261116,
  title        = {PDUFA dates February 2026: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2026-02}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2026_02_20261116","title":"PDUFA dates February 2026: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2026-02","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
